Topics:

Lung Cancer

On November 19, New York City Mayor Michael Bloomberg signed legislation (Tobacco 21 [Intro 250-A]) making New York the first major city to ban the sale of cigarettes, certain tobacco products, and e-cigarettes to anyone under 21 years of age, up from age 18.

Lung Cancer

A biomarker and five clinical factors help to predict which patients with nonsmall-cell lung cancer are at high risk for lung inflammation after radiotherapy.

The new ALK inhibitor certinib showed strong antitumor activity in a phase I expansion study of patients with advanced non-small-cell lung cancer (NSCLC).

In a phase I trial, non–small-cell lung cancer (NSCLC) patients with tumors that expressed PD-L1 had significantly better outcomes with MK-3475 therapy compared with patients with PD-L1–negative tumors.

In summary, central lung cancers, when appropriately staged, are optimally treated by surgical resection. Initial evaluation is best done by a multidisciplinary team, involving a trained thoracic surgeon.

Treatment optimization for centrally located lung cancers requires special considerations for determining resectability and patient selection.

Surgery continues to advance with the availability of new technology, knowledge and skills gained through experience, and collaboration between specialties. Some tumors that were unresectable in years past are now resectable. Other tumors that we currently consider beyond our ability to remove may be conquered in the near future.

We now have more tools than ever in the fight against tobacco-related death and disability, but unfortunately, there is not equal access to resources for smoking cessation, early lung cancer diagnosis, and treatment.

Pages

Subscribe to
Please Wait 20 seconds or click here to close